Prothena Corporation plc (PRTA) just the other week announced data from its phase 3 AFFIRM-AL clinical trial using birtamimab for the treatment of patients with AL amyloidosis. The really bad news ...
AbbVie is eyeing regulatory filings in 2027 for the skin disease drug lutikizumab after clearing multiple endpoints in a late ...
Global Phase 2b/3 Study Will Evaluate Symptom Duration and Hospitalization Rates in Adult Outpatients at High Risk of Severe Outcomes from RSV Topline Phase 2b Data Expected in 2027 Enanta ...
GSK may not have been surprised its anti-TIM-3 drug couldn’t secure a phase 3 win based on how its pharma peers have struggled. (iStock / Getty Images Plus) GSK’s cobolimab has become the latest ...
Two Sarepta Therapeutics drugs for treating different genetic subsets of patients with Duchenne muscular dystrophy failed the confirmatory study required of their accelerated FDA approvals. Sarepta ...
Financing co-led by Novo Holdings and the Ljungström family office, with participation from the originator Helsinn, existing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results